The frequency of aspirin resistance and its risk factors in patients with metabolic syndrome.
BACKGROUND
Although different populations were examined for the incidence of aspirin resistance, the frequency and related risk factors for aspirin resistance in patients with metabolic syndrome have not been reported yet. This study aimed to determine the frequency of aspirin resistance and its risk factors in patients with metabolic syndrome.


METHODS
We performed a cross-sectional study in 110 patients with metabolic syndrome. After one week of 100 mg/day aspirin, blood samples were obtained. Platelet function analyzer (PFA-100) was used to determine the frequency of aspirin resistance. Endothelial functions, carotid intima media thickness, and the presence of plaques in the carotid arteries were evaluated for subclinical atherosclerosis and the levels of inflammatory markers were assessed as risk factors for aspirin resistance. The presence of subclinical atherosclerosis was defined as a maximum carotid intima media thickness of > or = 0.9 mm and/or the presence of carotid atheroma.


RESULTS
Aspirin resistance was detected in 21.9% of the patients. In the multivariate analysis, hs-CRP levels (odds ratio [95% CI]=2.8 [1.3-5.9], p=0.009), diastolic blood pressure, (0.9 [0.8-1.0], p=0.007), and the presence of subclinical atherosclerosis (4.1 [1.4-12.2], p=0.012) were statistically significant risk factors for aspirin resistance.


CONCLUSIONS
We concluded that the frequency of aspirin resistance confirmed in this cohort of patients with metabolic syndrome was higher in patients with a lower diastolic blood pressure, higher hs-CRP levels and atherosclerotic changes in their carotid arteries.
Kahraman
Goksel
G
Department of Cardiology, Kocaeli University, School of Medicine, Umuttepe, Yerleskesi, Eski Istanbul Yolu 10. km, 41380 Kocaeli, Turkey. gokselkahraman@hotmail.com
Sahin
Tayfun
T
Kilic
Teoman
T
Baytugan
Nart Zafer
NZ
Agacdiken
Aysen
A
Ural
Ertan
E
Ural
Dilek
D
Komsuoglu
Baki
B
D000328:Adult; D000368:Aged; D001241:Aspirin / Q000008:administration & dosage*; D002318:Cardiovascular Diseases / Q000517:prevention & control; D016893:Carotid Stenosis / Q000517:prevention & control; D003430:Cross-Sectional Studies; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004351:Drug Resistance; D004730:Endothelium, Vascular / Q000187:drug effects / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood* / Q000188:drug therapy*; D008875:Middle Aged; D011336:Probability; D012307:Risk Factors; D012680:Sensitivity and Specificity; D018709:Statistics, Nonparametric; D017539:Tunica Intima / Q000187:drug effects / Q000473:pathology
D001241:Aspirin